U.S. RESEARCH ROUNDUP- ACV Auctions, Crown Castle, Lennox International

By Reuters News

Sept 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ACV Auctions, Crown Castle and Lennox International, on Monday.


HIGHLIGHTS

* ACV Auctions Inc. ACVA.N: Needham cuts to hold from buy

* Crown Castle Inc CCI.N: JP Morgan cuts to underweight from neutral

* Lennox International Inc. LII.N: Deutsche Bank cuts to hold from buy

Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.


* ACV Auctions Inc. ACVA.N: Needham cuts to hold from buy

* Crown Castle Inc CCI.N: JP Morgan cuts target price to $80 from $85

* Crown Castle Inc CCI.N: JP Morgan cuts to underweight from neutral

* Edison International EIX.N: Jefferies cuts target price to $53 from $68

* Korsana Biosciences, Inc. KRSA.O: TD Cowen initiates coverage with buy rating

* Kroger Co KR.N: Roth MKM cuts target price to $73 from $78

* Larimar Therapeutics, Inc. LRMR.O: Leerink Partners assumes coverage with outperform rating;

* Larimar Therapeutics, Inc. LRMR.O: Leerink Partners assumes coverage with target price $13 vs $12

* Lennox International Inc. LII.N: Deutsche Bank cuts target price to $444 from $609

* Lennox International Inc. LII.N: Deutsche Bank cuts to hold from buy

* Marathon Digital Holdings Inc MARA.O: JP Morgan cuts target price to $11 from $13

* Marathon Digital Holdings Inc MARA.O: JP Morgan cuts to underweight from overweight

* McCormick & Company, Incorporated MKC.N: TD Cowen cuts target price to $55 from $60

* McCormick & Company, Incorporated MKC.N: TD Cowen cuts to hold from buy

* PTC Therapeutics, Inc. PTCT.O: Leerink Partners assumes coverage with outperform vs market perform rating;

* PTC Therapeutics, Inc. PTCT.O: Leerink Partners assumes coverage with target price $98 vs $70

* Rhythm Pharmaceuticals, Inc. RYTM.O: Leerink Partners assumes coverage with outperform rating

* Rhythm Pharmaceuticals, Inc. RYTM.O: Leerink Partners assumes coverage with target price $133 vs $145

* X-Energy Inc XE.O: Texas Capital Securities initiates coverage with buy rating

* X-Energy Inc XE.O: Texas Capital Securities initiates coverage with target price $22

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.